Noorbakhsh, Javad
Farahmand, Saman http://orcid.org/0000-0001-8999-2322
Foroughi pour, Ali
Namburi, Sandeep http://orcid.org/0000-0003-3281-356X
Caruana, Dennis
Rimm, David http://orcid.org/0000-0001-5820-4397
Soltanieh-ha, Mohammad
Zarringhalam, Kourosh
Chuang, Jeffrey H. http://orcid.org/0000-0002-3298-2358
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA230031)
Article History
Received: 27 February 2020
Accepted: 5 November 2020
First Online: 11 December 2020
Competing interests
: D.L.R. has served as an advisor for Amgen, Astra Zeneca, BMS, Cell Signaling Technology, Cepheid, Daiichi Sankyo, Danaher, GSK, Konica/Minolta, Merck, Nanostring, NextCure, Odonate, Perkin Elmer, PAIGE.AI, Roche, Sanofi, Ventana, and Ultivue, and he has equity in PixelGear and receives royalties from Rarecyte. He has received instrument support from Ventana, Akoya/Perkin Elmer, and Nanostring. Amgen, Cepheid, Navigate BioPharma, NextCure, Konica/Minolta, Lilly, and Ultivue fund research in D.L.R.’s lab. The remaining authors declare no competing interests.